- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06654882
청소년 특발성 관절염에서 TNFi 실패 후 순차적 약물 투여에 대한 시험 (SMART-JIA)
This study is an open-label, randomized, multicenter trial that incorporates a multi-arm design comparing each of 3 non-TNFi (Tumor Necrosis Factor inhibitor) medications to a second TNFi (active control) within a sequential multiple assignment randomized trial design with 2 randomization stages corresponding with clinical decision points. The first randomization addresses whether each of the 3 non-TNFi medications is superior to treatment with a second TNFi. The second randomization allows identification of optimal sequential use of biologics (treatment strategies).
연구 개요
상태
상세 설명
The goal of the study is to provide an evidence base for selecting sequential medication(s) if a JIA patient fails initial bDMARD. SMART-JIA is a pragmatic, international, open-label, randomized trial comparing treatment with a second TNFi (active control) to each of 3 different medications (IL-6i, JAKi, or ABA) in children aged 2 to 21 years with pcJIA and inadequate response to initial TNFi. Leveraging sequential multiple assignment randomized trial (SMART) design methodology, we will implement a second randomization to assess the effectiveness of changing medication if there is inadequate response to the first study medication. This approach allows identification of optimal strategies for medication sequencing based on individual characteristics and provides critical insights to inform future studies.
SMART-JIA will study the efficacy of a second TNFi (active control) compared to each of 3 other already US Food and Drug Administration (FDA)-approved and European Union (EU)-approved non-TNFi medications currently used to treat pcJIA (IL-6i, JAKi, and ABA). TNFi, IL-6i, and ABA are administered by subcutaneous (SQ) injection weekly, or every other week, or every three weeks, and JAKi (e.g., tofacitinib) is taken orally twice daily. All study treatments have similar safety profiles and are standard of care (SOC) worldwide. This in addition to the pragmatic and full-scale nature of the trial will ensure its completion. Successful completion of this trial will substantially impact the clinical care and outcomes of children with pcJIA, shifting the current trial-and-error treatment paradigm to a smart, precise approach.
연구 유형
등록 (추정된)
단계
- 3단계
연락처 및 위치
연구 연락처
- 이름: Laura E Schanberg (Contact PI)
- 전화번호: 919-373-3863
- 이메일: laura.schanberg@duke.edu
연구 연락처 백업
- 이름: Huiman Barnhart (Dual PI)
- 전화번호: 919-668-8828
- 이메일: huiman.barnhart@duke.edu
연구 장소
-
-
Utrecht
-
Utrecht, Utrecht, 네덜란드, 3584 CX
- 모병
- University Medical Center Utrecht (Universitair Medisch Centrum Utrecht)
-
연락하다:
- Sabine Michel Site Study Coordinator
- 전화번호: +31 88 755 5555
- 이메일: S.Michel-2@umcutrecht.nl
-
연락하다:
- Jojanneke J. Scheepstra Site Study Coordinator
- 전화번호: +31 88 755 5555
- 이메일: J.Scheepstra@umcutrecht.nl
-
수석 연구원:
- Joost Swart
-
-
-
-
North Rhine-Westphalia
-
Sankt Augustin, North Rhine-Westphalia, 독일, 53757
- 모병
- Asklepios Children's Hospital
-
연락하다:
- Jana Kipp
- 전화번호: +49 (2241) 249-201
- 이메일: j.kipp@asklepios.com
-
연락하다:
- Verena Lutz-Wiegers
- 이메일: v.lutz@asklepios.com
-
수석 연구원:
- Gerd Horneff, Prof. Dr.
-
-
-
-
California
-
San Francisco, California, 미국, 94158
- 모병
- University of California San Francisco Pediatric Rheumatology
-
연락하다:
- Study Coordinator
- 전화번호: 415-353-1301
- 이메일: zilan.zheng@ucsf.edu
-
수석 연구원:
- Susan Kim
-
-
Florida
-
Gainesville, Florida, 미국, 32610
- 모병
- University of Florida
-
수석 연구원:
- Melissa Elder
-
연락하다:
- Study Coordinator
- 전화번호: 352-294-8556
- 이메일: melissa.lingis@peds.ufl.edu
-
-
New Jersey
-
Hackensack, New Jersey, 미국, 07601
- 모병
- Hackensack Meridian Health - Joseph M. Sanzari Children's Hospital
-
수석 연구원:
- Ginger Janow
-
연락하다:
- Clinical Research Coordinator
- 전화번호: 551-996-3345
- 이메일: kate.sidwell@hmhn.org
-
-
Ohio
-
Columbus, Ohio, 미국, 43205
- 모병
- Nationwide Children's Hospital
-
연락하다:
- Study Coordinator
- 전화번호: 614-722-5525
- 이메일: joanne.drew@nationwidechildrens.org
-
수석 연구원:
- Alysha Taxter
-
-
-
-
Liguria
-
Genoa, Liguria, 이탈리아, 16147
- 모병
- IRCCS Giannina Gaslini Institute
-
연락하다:
- Research Assistant
- 전화번호: +39 010 56361
- 이메일: elisapatrone@gaslini.org
-
수석 연구원:
- Alessandro Consolaro
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Polyarticular course JIA
- Moderate or high-disease activity (cJADAS10 >5) despite treatment with an initial TNFi for ≥2 months
- Age ≥2 years and <21 years and weight ≥ 10kg
- No systemic glucocorticoids or systemic glucocorticoids at a stable dose of ≤0.2 mg/kg/day (maximum 10 mg/day) for ≥2 weeks prior to baseline visit
- Documented informed consent/assent obtained from the parent/caregiver/patient
Exclusion Criteria:
- Systemic JIA
- Enthesitis-related arthritis/juvenile spondyloarthritis (2001 International League of Associations for Rheumatology [ILAR] criteria)30
- History of or currently active inflammatory bowel disease
- History of or currently active psoriasis
- Active uveitis within 3 months of the baseline visit
- History of or currently active sacroiliitis
- History of or current malignancy
- Active tuberculosis (TB) or a history of incompletely treated TB; Purified Protein derivative (PPD) or QuantiFERON-TB positive patients (without active TB) unless it is documented that the patient has been adequately treated for TB and can start treatment with a biologic agent, based on the medical judgment of the site investigator and/or an infectious disease specialist; suspected extrapulmonary TB infection; or at high risk of contracting TB, such as close contact with individual with active or latent TB
- Prior treatment with more than one TNFi molecule; exposure to more than one biosimilar of the same TNFi molecule is allowed
- Prior treatment with non-TNFi bDMARDs and/or any JAKi
- Aspartate aminotransferase (AST) or alanine transaminase (ALT) ≥3 × upper limit of normal (ULN) for age and sex
- Serum creatinine >1.5 × ULN for age and sex
- Platelet count <150 × 103/μL (<150,000/mm3)
- Hemoglobin <7.0 g/dL (<4.3 mmol/L)
- White blood cell (WBC) count <3,000/mm3 (<3.0 × 109/L)
- Neutrophil count <1,500/mm3 (<1.5 × 109/L)
- Any active acute, subacute, chronic, or recurrent bacterial, viral, or systemic fungal infection or any major episode of infection requiring hospitalization or treatment during screening or treatment with IV antibiotics completed within 4 weeks of the screening visit or oral antibiotics completed within 2 weeks of the screening visit
- Any live attenuated vaccine, such as varicella-zoster, oral polio, measles, mumps or rubella vaccines, within 4 weeks prior to the baseline visit.
- Any medical history that may be considered a contraindication/safety concern with the use of adalimumab, etanercept, tofacitinib, ABA, or an IL-6 inhibitor or their biosimilars. In particular, subjects at known high risk for venous thromboembolism will be excluded, including recent heart failure or prior myocardial infarction, known inherited thrombotic risk factors, history of venous thromboembolism (deep venous thrombosis or pulmonary embolism, undergoing major surgery, or are chronically immobilized).
- Pregnant or breastfeeding
- Sexually active females of childbearing potential who refuse to use at least one required contraception method (See Contraception paragraph 8.9 for definition of childbearing potential and details).
- History of hypersensitivity or allergic reaction to any study drug or any of its excipients (inactive ingredients).
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: Second TNFi (Tumor Necrosis Factor inhibitor) medication
Adalimumab originator or biosimilar; etanercept originator or biosimilar depending on which TNFi the participant had failed. |
Adalimumab 10 kg (22 lbs) to <15 kg (33 lbs) 10 mg every other week* 15 kg (33 lbs) to <30 kg (66 lbs) 20 mg every other week ≥30 kg (66 lbs) 40 mg every other week Etanercept ≥63 kg (138 lb) 50 mg weekly <63 kg (138 lb) 0.8 mg/kg weekly |
|
활성 비교기: Abatacept
The 50 mg, 87.5 mg and 125 mg SQ doses will be available for weight-based dosing. All participants randomized to abatacept in the first or second stage randomization will receive abatacept SQ weekly at a dosage based on the participant's body weight |
10 kg to <25 kg 50 mg once weekly 25 kg to <50 kg 87.5 mg once weekly ≥50 kg 125 mg once weekly |
|
활성 비교기: Tocilizumab originator or biosimilar
Tocilizumab will be provided in prefilled syringes (162 mg tocilizumab/0.9 mL solution). All participants randomized to tocilizumab in the first or second stage randomization will be receiving 1 prefilled syringe (162 mg) with a dosing interval based on the body weight criteria. |
<30 kg 162 mg once every 3 weeks ≥30 kg 162 mg once every 2 weeks |
|
활성 비교기: Tofacitinib
Tofacitinib will be provided as oral tablets (tofacitinib citrate 5 mg) and as an oral solution (1 mg/mL). All participants randomized to tofacitinib in the first or second stage randomization will receive tofacitinib oral tablets or oral solution twice daily, approximately 12 hours apart, in the morning and evening, at a dosage based on the participant's body weight . |
10 to <20 kg 3.2 mg (3.2 mL oral solution) BID 20 to <40 kg 4 mg (4 mL oral solution) BID ≥40 kg 5 mg (one 5 mg tablet or 5 mL oral solution) BID |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of participants with MiDA
기간: Month 6
|
Minimal disease activity (MiDA) at Month 6 as assessed by the cJADAS10 ≤5 MiDA is low-disease activity and inactive disease in this protocol. Score range for the cJADAS10 (total): 0 - 30. Disease State cJADAS10 Score Inactive disease ≤2.5 Low-disease activity 2.6 - 5 Moderate-disease activity 5.1 - 16 High-disease activity >16 Minimal disease activity (MiDA) is a state of low disease activity or remission that is considered a useful treatment target for both patients and physicians. The clinical Juvenile Arthritis Disease Activity Score (cJADAS10) is a tool used to measure the level of disease activity in non-systemic juvenile idiopathic arthritis (JIA). It's a composite index that combines information from several sources, including:
|
Month 6
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
PROMIS® Pain Interference at Month 6
기간: Month 6
|
Patient-Reported Outcomes Measurement Information System (PROMIS). For most PROMIS instruments, a score of 50 is the average for the United States general population with a standard deviation of 10 because calibration testing was performed on a large sample of the general population. For PROMIS measures, higher scores equals more of the concept being measured (e.g., more Fatigue, more Physical Function). Thus a score of 60 is one standard deviation above the average referenced population. This could be a desirable or undesirable outcome, depending upon the concept being measured. |
Month 6
|
|
PROMIS® Fatigue at Month 6
기간: Month 6
|
Patient-Reported Outcomes Measurement Information System (PROMIS). For most PROMIS instruments, a score of 50 is the average for the United States general population with a standard deviation of 10 because calibration testing was performed on a large sample of the general population. For PROMIS measures, higher scores equals more of the concept being measured (e.g., more Fatigue, more Physical Function). Thus a score of 60 is one standard deviation above the average referenced population. This could be a desirable or undesirable outcome, depending upon the concept being measured. |
Month 6
|
|
PROMIS® Physical Function at Month 6
기간: Month 6
|
Patient-Reported Outcomes Measurement Information System (PROMIS). For most PROMIS instruments, a score of 50 is the average for the United States general population with a standard deviation of 10 because calibration testing was performed on a large sample of the general population. For PROMIS measures, higher scores equals more of the concept being measured (e.g., more Fatigue, more Physical Function). Thus a score of 60 is one standard deviation above the average referenced population. This could be a desirable or undesirable outcome, depending upon the concept being measured. |
Month 6
|
|
Change in arthritis disease activity (cJADAS10)
기간: Month 6
|
Minimal disease activity (MiDA) at Month 6 as assessed by the cJADAS10 ≤5 MiDA is low-disease activity and inactive disease in this protocol. Score range for the cJADAS10 (total): 0 - 30. Disease State cJADAS10 Score Inactive disease ≤2.5 Low-disease activity 2.6 - 5 Moderate-disease activity 5.1 - 16 High-disease activity >16 Minimal disease activity (MiDA) is a state of low disease activity or remission that is considered a useful treatment target for both patients and physicians. |
Month 6
|
|
Change in arthritis disease activity (JIA American College of Rheumatology Pediatric 70 [ACR 70]) at Month 6
기간: Month 6
|
The ACR score is a scale to measure change in rheumatoid arthritis symptoms. An ACR70 response represents at least a 70% improvement in tender and swollen joint counts. |
Month 6
|
|
Number of participants with MiDA (Change in arthritis disease activity [cJADAS10] at Month 12)
기간: Month 12
|
Minimal disease activity (MiDA) at Month 12 as assessed by the cJADAS10 ≤5 MiDA is low-disease activity and inactive disease in this protocol. Score range for the cJADAS10 (total): 0 - 30. Disease State cJADAS10 Score Inactive disease ≤2.5 Low-disease activity 2.6 - 5 Moderate-disease activity 5.1 - 16 High-disease activity >16 Minimal disease activity (MiDA) is a state of low disease activity or remission that is considered a useful treatment target for both patients and physicians. |
Month 12
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- Pro00115808
- PLACER-2022C3-30331 (기타 보조금/기금 번호: PCORI)
- EPM #8533 (기타 보조금/기금 번호: DukeUMC)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .